Megestrol Oncoeurope

Megestrol acetate, the active ingredient in Megestrol Oncoeurope, is a progestin presented as an oral tablet for oral use. It treats cachexia and anorexia associated with AIDS or cancer and is employed in hormone‑responsive cancers such as advanced breast cancer, endometrial carcinoma, and certain gynecologic tumors.

GNH USA supplies Megestrol Oncoeurope as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Megestrol acetate is indicated for conditions involving hormonal pathways and cancer‑related weight loss. - Cachexia and anorexia associated with AIDS or cancer: improves appetite and promotes weight gain. - Advanced breast cancer: provides antineoplastic effect in hormone‑responsive disease. - Endometrial carcinoma: used as hormonal therapy to control tumor growth.

Megestrol acetate may cause a range of adverse reactions.

Common Side Effects: - Weight gain: increased adipose tissue accumulation. - Edema: fluid retention leading to swelling. - Nausea: mild gastrointestinal discomfort. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal suppression: cortisol deficiency. - Hyperglycemia: elevated blood glucose levels. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, consider the following precautions. - Assess baseline weight and nutritional status: monitor changes regularly. - Screen for thromboembolic risk: evaluate history of clotting disorders. - Monitor blood glucose: especially in diabetic patients. - Check liver function: adjust if hepatic impairment is present. - Avoid use in pregnancy unless benefits outweigh risks: limited safety data. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Megestrol acetate can interact with several drug classes.

Major Interactions (Avoid): - Anticoagulants: may increase bleeding risk. - CYP3A4 inducers (e.g., rifampin, phenytoin): reduce efficacy. - CYP3A4 inhibitors (e.g., ketoconazole): increase exposure.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: may worsen hyperglycemia. - Other hormonal therapies: additive endocrine effects. - Corticosteroids: overlapping glucocorticoid activity.